Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2012 2
2013 3
2014 1
2015 1
2016 2
2017 4
2018 2
2019 2
2021 1
2022 4
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. Drysdale SB, et al. N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189. N Engl J Med. 2023. PMID: 38157500 Clinical Trial.
Mpox in people with past infection or a complete vaccination course: a global case series.
Hazra A, Zucker J, Bell E, Flores J, Gordon L, Mitjà O, Suñer C, Lemaignen A, Jamard S, Nozza S, Nori AV, Pérez-Barragán E, Rodríguez-Aldama JC, Blanco JL, Delaugerre C, Turner D, Fuertes I, Leiro V, Walmsley SL, Orkin CM; SHARE-NET writing group. Hazra A, et al. Lancet Infect Dis. 2024 Jan;24(1):57-64. doi: 10.1016/S1473-3099(23)00492-9. Epub 2023 Sep 4. Lancet Infect Dis. 2024. PMID: 37678309 Free article.
Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.
Durier C, Ninove L, Lefebvre M, Radenne A, Desaint C, Ropers J, Bauer R, Lebbah S, Carette D, Lachatre M, Lecompte AS, Deplanque D, Botelho-Nevers E, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian J, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Priet S, Levier A, Molino D, Vieillard LV, Parfait B, Lelièvre JD, Tartour E, de Lamballerie X, Launay O; ANRS0002S CoviCompareP Group; AP-HP CoviCompareM Group; Biological resource centers; Laboratories; Trial coordination; Sponsor; Scientific Committee. Durier C, et al. Among authors: maakaroun vermesse z. Sci Rep. 2022 Nov 27;12(1):20373. doi: 10.1038/s41598-022-24409-w. Sci Rep. 2022. PMID: 36437298 Free PMC article.
[Gastrointestinal parasitic carriage in adopted children].
Desoubeaux G, Collin-Dorca A, Guillon-Grammatico L, Dimier-Poisson I, Bez S, Bailly É, Bernard L, Maakaroun-Vermesse Z, Chandenier J. Desoubeaux G, et al. Among authors: maakaroun vermesse z. Arch Pediatr. 2016 Jul;23(7):685-94. doi: 10.1016/j.arcped.2016.04.005. Epub 2016 Jun 7. Arch Pediatr. 2016. PMID: 27287709 French.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. de Bruyn G, et al. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37533419 Free PMC article.
Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial.
Janssen C, Cachanado M, Ninove L, Lachatre M, Michon J, Epaulard O, Maakaroun-Vermesse Z, Chidiac C, Laviolle B, Aumaitre H, Assaf A, Lacombe K, Schmidt-Mutter C, Botelho-Nevers E, Briere M, Boisson T, Loubet P, Bienvenu B, Bouchaud O, Touati A, Pereira C, Rousseau A, Berard L, Montil M, de Lamballerie X, Simon T, Launay O; ARNCOMBI Study Group. Janssen C, et al. Among authors: maakaroun vermesse z. EClinicalMedicine. 2022 Jun;48:101444. doi: 10.1016/j.eclinm.2022.101444. Epub 2022 May 12. EClinicalMedicine. 2022. PMID: 35582124 Free PMC article.
Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area.
Gaborit BJ, Revest M, Roblot F, Maakaroun-Vermesse Z, Bemer P, Guimard T, Raffi F, Bourigault C, Boutoille D; GERICCO MDR-TB study group. Gaborit BJ, et al. Among authors: maakaroun vermesse z. Med Mal Infect. 2018 Oct;48(7):457-464. doi: 10.1016/j.medmal.2018.04.400. Epub 2018 Jun 7. Med Mal Infect. 2018. PMID: 29887187
28 results